Amneal Pharmaceuticals (AMRX) Total Debt (2017 - 2026)

Amneal Pharmaceuticals' Total Debt history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• In Q1 2026, Total Debt rose 17.66% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (up 17.66% YoY), while the FY2025 annual figure was $2.6 billion, up 7.79% from the prior year.
• Total Debt was $2.6 billion for Q1 2026 at Amneal Pharmaceuticals, roughly flat from $2.6 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $2.7 billion in Q4 2022 to a low of $68.8 million in Q2 2022.
• Historically, Total Debt has averaged $2.1 billion across 5 years, with a median of $2.4 billion in 2025.
• Biggest YoY gain for Total Debt was 3762.93% in 2022; the steepest drop was 97.5% in 2022.
• A 5-year view of Total Debt shows it stood at $2.7 billion in 2022, then fell by 8.74% to $2.4 billion in 2023, then retreated by 1.41% to $2.4 billion in 2024, then rose by 7.79% to $2.6 billion in 2025, then retreated by 0.0% to $2.6 billion in 2026.
• The last three Total Debt figures came in at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.